Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | S100A4 | P26447 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8589532 | 0.98 | GPR35 (0.62) | GPR35TSHRTDP1CA1CA2 | |
| Sulfuric Acid SCHEMBL8589539 | 0.92 | GPR35 (0.60) | GPR35TSHRTDP1CA1CA2 | |
| SCHEMBL27637844 | 0.92 | TSHR (0.60) | GPR35TSHRTDP1CA1CA2 | |
| SCHEMBL1926046 | 0.89 | TSHR (0.71) | GPR35TSHRTDP1CA1CA2 | |
| SCHEMBL118464 | 0.89 | TSHR (0.71) | GPR35TSHRTDP1CA1CA2 | |
| SCHEMBL9138180 | 0.87 | TSHR (0.59) | GPR35TSHRTDP1CA1CA2 | |
| Sulfuric Acid SCHEMBL8589534 | 0.87 | GPR35 (0.59) | GPR35TSHRTDP1CA1CA2 | |
| Sulfuric Acid SCHEMBL27814115 | 0.87 | GPR35 (0.55) | GPR35TSHRTDP1CA1CA2 | |
| Fluoride SCHEMBL29099623 | 0.86 | TSHR (0.68) | GPR35TSHRTDP1KMT2AMEN1 | |
| SCHEMBL28529002 | 0.86 | TSHR (0.68) | GPR35TSHRTDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023194433-A1 | PHARMACEUTICAL COMPOSITION BASED ON VORAPAXAR AND USE THEREOF FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASES | CVASTHERA (FR) | 2023-10-12 | — | — | WO | disclosed |
| EP-3897633-B1 | USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF A CHRONIC INFLAMMATORY INTESTINAL DISEASE | CVASTHERA (FR) | 2023-06-07 | — | — | EP | disclosed |
| CN-111701078-B | Method for improving cross-linking degree of biological tissue | 上海以心医疗器械有限公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3897633-A1 | USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF A CHRONIC INFLAMMATORY INTESTINAL DISEASE | Cvasthera (FR) | 2021-10-27 | — | — | EP | disclosed |
| CN-111701078-A | Method for improving cross-linking degree of biological tissue | 上海以心医疗器械有限公司 | 2020-09-25 | — | — | CN | disclosed |
| WO-2020127539-A1 | USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF A CHRONIC INFLAMMATORY INTESTINAL DISEASE | CVASTHERA (FR) | 2020-06-25 | — | — | WO | disclosed |
| CN-109125810-A | A kind of preparation method of biovalve | 上海微创心通医疗科技有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20180360786-A1 | (R)-CARBIDOPA ALONE OR IN COMBINATION WITH A STEROID FOR TREATING PAIN, INFLAMMATION, AN INFLAMMATORY DISEASE, AN IMMUNE OR AUTOIMMUNE DISEASE AND TUMOUR GROWTH | Proximagen Group Limited (GB) | 2018-12-20 | — | — | US | disclosed |
| CN-108778264-A | For treating pain, inflammation, inflammatory disease, immune or autoimmune disease and tumour growth individual or with steroid combination (R)-carbidopa | 普罗克斯马根集团有限公司 | 2018-11-09 | — | — | CN | disclosed |
| EP-3386497-A1 | (R)-CARBIDOPA ALONE OR IN COMBINATION WITH A STEROID FOR TREATING PAIN, INFLAMMATION, AN INFLAMMATORY DISEASE, AN IMMUNE OR AUTOIMMUNE DISEASE AND TUMOUR GROWTH. | Proximagen Group Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| CN-101011576-A | Compositions and methods for treating or preventing inflammatory diseases | ANGIOTECH PHARM INC (CH) | 2007-08-08 | — | — | CN | disclosed |
| CN-1997667-A | Humanized FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS INC (US) | 2007-07-11 | — | — | CN | disclosed |
| US-7067254-B2 | Diagnosis and treatment of inflammation and hyperactive immune conditions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1679937-A | Compositions and methods for treating or preventing inflammatory diseases | ANGIOTECH INT AG (CH) | 2005-10-12 | — | — | CN | disclosed |
| CN-1200706-C | Compositions and methods for treating or preventing inflammatory diseases | BLOOD VESSEL TECHNOLOGY INTERN (CH) | 2005-05-11 | — | — | CN | disclosed |
| US-20040173933-A1 | Double-layer hollow membrane for bio-reactor applications | GKSS FORSCHUNGSZENTRUM GEESTHACHT GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20030087247-A1 | Diagnosis and treatment of inflammation and hyperactive immune conditions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-05-08 | — | — | US | disclosed |
| WO-2002071062-A9 | DIAGNOSIS AND TREATMENT OF INFLAMMATION AND HYPERACTIVE IMMUNE CONDITIONS | UNIV TEXAS (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002071062-A2 | DIAGNOSIS AND TREATMENT OF INFLAMMATION AND HYPERACTIVE IMMUNE CONDITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-09-12 | — | — | WO | disclosed |
| CN-1246791-A | Compositions and methods for treating or preventing inflammatory diseases | ANGIOTECH PHARM INC (CA) | 2000-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360786-A1 | (R)-CARBIDOPA ALONE OR IN COMBINATION WITH A STEROID FOR TREATING PAIN, INFLAMMATION, AN INFLAMMATORY DISEASE, AN IMMUNE OR AUTOIMMUNE DISEASE AND TUMOUR GROWTH | MC2R, ADCYAP1R1, PTGDR | GPR35 90/4885TSHR 700/4885TDP1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.